273 related articles for article (PubMed ID: 17315048)
21. Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients.
Breccia M; Alimena G
BioDrugs; 2011 Jun; 25(3):147-57. PubMed ID: 21528941
[TBL] [Abstract][Full Text] [Related]
22. Dasatinib.
Lindauer M; Hochhaus A
Recent Results Cancer Res; 2014; 201():27-65. PubMed ID: 24756784
[TBL] [Abstract][Full Text] [Related]
23. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Brave M; Goodman V; Kaminskas E; Farrell A; Timmer W; Pope S; Harapanhalli R; Saber H; Morse D; Bullock J; Men A; Noory C; Ramchandani R; Kenna L; Booth B; Gobburu J; Jiang X; Sridhara R; Justice R; Pazdur R
Clin Cancer Res; 2008 Jan; 14(2):352-9. PubMed ID: 18223208
[TBL] [Abstract][Full Text] [Related]
24. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Piccaluga PP; Paolini S; Martinelli G
Cancer; 2007 Sep; 110(6):1178-86. PubMed ID: 17701954
[TBL] [Abstract][Full Text] [Related]
25. The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.
Hochhaus A; Kantarjian H
J Cancer Res Clin Oncol; 2013 Dec; 139(12):1971-84. PubMed ID: 23942795
[TBL] [Abstract][Full Text] [Related]
26. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
[TBL] [Abstract][Full Text] [Related]
27. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Keam SJ
BioDrugs; 2008; 22(1):59-69. PubMed ID: 18215092
[TBL] [Abstract][Full Text] [Related]
28. Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic.
Klamova H; Faber E; Zackova D; Markova M; Voglova J; Cmunt E; Novakova L; Machova-Polakova K; Moravcova J; Dvorakova D; Michalova K; Brezinova J; Oltova A; Jarosova M; Cetkovsky P; Indrak K; Mayer J
Neoplasma; 2010; 57(4):355-9. PubMed ID: 20429627
[TBL] [Abstract][Full Text] [Related]
29. Practical management of dasatinib for maximum patient benefit.
Galinsky I; Buchanan S
Clin J Oncol Nurs; 2009 Jun; 13(3):329-35. PubMed ID: 19502192
[TBL] [Abstract][Full Text] [Related]
30. Dasatinib: an anti-tumour agent via Src inhibition.
Gnoni A; Marech I; Silvestris N; Vacca A; Lorusso V
Curr Drug Targets; 2011 Apr; 12(4):563-78. PubMed ID: 21226671
[TBL] [Abstract][Full Text] [Related]
31. Dasatinib for the treatment of chronic myeloid leukemia.
Fullmer A; Kantarjian H; Cortes J; Jabbour E
Expert Rev Hematol; 2011 Jun; 4(3):253-60. PubMed ID: 21668392
[TBL] [Abstract][Full Text] [Related]
32. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.
Müller MC; Cortes JE; Kim DW; Druker BJ; Erben P; Pasquini R; Branford S; Hughes TP; Radich JP; Ploughman L; Mukhopadhyay J; Hochhaus A
Blood; 2009 Dec; 114(24):4944-53. PubMed ID: 19779040
[TBL] [Abstract][Full Text] [Related]
33. [Research advance on molecular genetics of CML blast crisis].
Zhu HQ; Zhang S; Liu XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
[TBL] [Abstract][Full Text] [Related]
34. Treatment of chronic myeloid leukemia following imatinib resistance: a nursing guide to second-line treatment options.
Bauer S; Romvari E
Clin J Oncol Nurs; 2009 Oct; 13(5):523-34. PubMed ID: 19793709
[TBL] [Abstract][Full Text] [Related]
35. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
[TBL] [Abstract][Full Text] [Related]
36. The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms.
Amrein PC
Leuk Lymphoma; 2011 May; 52(5):754-63. PubMed ID: 21463117
[TBL] [Abstract][Full Text] [Related]
37. Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis.
Snead JL; O'Hare T; Adrian LT; Eide CA; Lange T; Druker BJ; Deininger MW
Blood; 2009 Oct; 114(16):3459-63. PubMed ID: 19706883
[TBL] [Abstract][Full Text] [Related]
38. A once-daily dasatinib dosing strategy for chronic myeloid leukemia.
Bryant G
Clin J Oncol Nurs; 2009 Jun; 13(3):316-23. PubMed ID: 19502190
[TBL] [Abstract][Full Text] [Related]
39. Dasatinib and chronic myeloid leukemia: two-year follow-up in eight clinical trials.
Pavlů J; Marin D
Clin Lymphoma Myeloma; 2009 Dec; 9(6):417-24. PubMed ID: 19951880
[TBL] [Abstract][Full Text] [Related]
40. [Development of Ph negative acute myeloid leukemia in a patient with minor-BCR/ABL positive chronic myeloid leukemia achieving a partial cytogenetic response during tyrosine kinase inhibitor treatment].
Fujii S; Miura I; Tanaka H
Rinsho Ketsueki; 2015 Jun; 56(6):681-6. PubMed ID: 26256879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]